Your browser doesn't support javascript.
loading
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Corbett, Kizzmekia S; Edwards, Darin K; Leist, Sarah R; Abiona, Olubukola M; Boyoglu-Barnum, Seyhan; Gillespie, Rebecca A; Himansu, Sunny; Schäfer, Alexandra; Ziwawo, Cynthia T; DiPiazza, Anthony T; Dinnon, Kenneth H; Elbashir, Sayda M; Shaw, Christine A; Woods, Angela; Fritch, Ethan J; Martinez, David R; Bock, Kevin W; Minai, Mahnaz; Nagata, Bianca M; Hutchinson, Geoffrey B; Wu, Kai; Henry, Carole; Bahl, Kapil; Garcia-Dominguez, Dario; Ma, LingZhi; Renzi, Isabella; Kong, Wing-Pui; Schmidt, Stephen D; Wang, Lingshu; Zhang, Yi; Phung, Emily; Chang, Lauren A; Loomis, Rebecca J; Altaras, Nedim Emil; Narayanan, Elisabeth; Metkar, Mihir; Presnyak, Vlad; Liu, Cuiping; Louder, Mark K; Shi, Wei; Leung, Kwanyee; Yang, Eun Sung; West, Ande; Gully, Kendra L; Stevens, Laura J; Wang, Nianshuang; Wrapp, Daniel; Doria-Rose, Nicole A; Stewart-Jones, Guillaume; Bennett, Hamilton.
Afiliación
  • Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Edwards DK; Moderna Inc, Cambridge, MA, USA.
  • Leist SR; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Abiona OM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Boyoglu-Barnum S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Gillespie RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Himansu S; Moderna Inc, Cambridge, MA, USA.
  • Schäfer A; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ziwawo CT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • DiPiazza AT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Dinnon KH; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Elbashir SM; Moderna Inc, Cambridge, MA, USA.
  • Shaw CA; Moderna Inc, Cambridge, MA, USA.
  • Woods A; Moderna Inc, Cambridge, MA, USA.
  • Fritch EJ; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Martinez DR; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Bock KW; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Minai M; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Nagata BM; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Hutchinson GB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Wu K; Moderna Inc, Cambridge, MA, USA.
  • Henry C; Moderna Inc, Cambridge, MA, USA.
  • Bahl K; Moderna Inc, Cambridge, MA, USA.
  • Garcia-Dominguez D; Moderna Inc, Cambridge, MA, USA.
  • Ma L; Moderna Inc, Cambridge, MA, USA.
  • Renzi I; Moderna Inc, Cambridge, MA, USA.
  • Kong WP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Schmidt SD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Wang L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Zhang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Phung E; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Chang LA; Institute for Biomedical Sciences, George Washington University, Washington, DC, USA.
  • Loomis RJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Altaras NE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Narayanan E; Moderna Inc, Cambridge, MA, USA.
  • Metkar M; Moderna Inc, Cambridge, MA, USA.
  • Presnyak V; Moderna Inc, Cambridge, MA, USA.
  • Liu C; Moderna Inc, Cambridge, MA, USA.
  • Louder MK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Shi W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Leung K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • West A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Gully KL; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Stevens LJ; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Wang N; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Wrapp D; Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
  • Doria-Rose NA; Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
  • Stewart-Jones G; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Bennett H; Moderna Inc, Cambridge, MA, USA.
Nature ; 586(7830): 567-571, 2020 10.
Article en En | MEDLINE | ID: mdl-32756549
ABSTRACT
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity1. This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant2 SARS-CoV-2 as well as CD8+ T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Vacunas Virales / Infecciones por Coronavirus / Pandemias / Betacoronavirus Límite: Animals Idioma: En Revista: Nature Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Vacunas Virales / Infecciones por Coronavirus / Pandemias / Betacoronavirus Límite: Animals Idioma: En Revista: Nature Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos